Patent Cliffs And Drug Sales 2016 Versus 2006, And Beyond
With pharma's tumble over the patent cliff reaching terminal velocity in 2015, a comparison of the top 10 products by global sales in 2016 with 2006 looks very different. But analysts forecast that the table will be headed by the same product – Humira – right out to 2025 despite a second impending cliff.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.